Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers

Journal of Cancer Research and Clinical Oncology

Volumn 132, Issue 4, 2006, Pages 265-274

  Gückel, Brigitte ^a   Rentzsch, Christine ^a   Nastke, Maria Dorothea ^b   Marmé, Alexander ^a   Gruber, Ines ^a   Stevanović, Stefan ^b   Kayser, Simone ^a   Wallwiener, Diethelm ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Breast cancer; Immunotherapy; MUC 1; Mucin; T cells

Indexed keywords

CD40 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANZYME B; HLA A ANTIGEN; MUCIN 1; TUMOR ANTIGEN;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CELL SPECIFICITY; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; LYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR IMMUNITY;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; B-LYMPHOCYTES; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MUCIN-1; MUCINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 31344432660     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-005-0064-6     Document Type: Article

References (36)

1. Agrawal B, Reddish MA, Krantz MJ, Longenecker BM (1995) Does pregnancy immunize against breast cancer? Cancer Res 55:2257-2261
2. Agrawal B, Reddish MA, Longenecker BM (1996) In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 157:2089-2095
3. Apostolopoulos V, Pietersz GA, McKenzie IF (1999) MUC1 and breast cancer. Curr Opin Mol Ther 1:98-103
4. Barnd DL, Lan MS, Metzgar RS, Finn OJ (1989) Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86:7159-7163
5. Bednarek MA, Engl SA, Gammon MC, Lindquist JA, Porter G, Williamson AR , et al (1991) Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytes. J Immunol Methods 139:41-47
6. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, et al (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309-4317
7. Brossart P, Wirths S, Stuhler G, Reichard VL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102-3108
8. Cui Z, Willingham MC (2004) Halo naevus: a visible case of immunosurveillance in humans? Lancet Oncol 5(7):397-398
9. Darnell RB, Posner JB (2003) Observing the invisible: successful tumor immunity in humans. Nat Immunol 4(3):201
10. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG (2000) Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 62:245-252
11. Dittmann J, Keller-Matschke K, Weinschenk T, Kratt T, Heck T, Becker HD et al (2004) CD8(+) T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors. Cancer Immunol Immunother 54:750-758
12. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diehl IJ, et al (2001) Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7:552-458
13. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, et al (1995) MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145:61-89
14. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, et al (2000) Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6:1693-1701
15. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT (1996) A phase I trial of a synthetic mucin peptide vaccine Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63(1):298-304
16. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ (1993) Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151:3693-3703
17. Kammula US, Marincola FM, Rosenberg SA (2000) Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 92:1336-1344
18. Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, et al (1997) Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100(11):2783-2792
19. Kayser S, Watermann I, Rentzsch C, Weinschenk T, Wallwiener D, Gückel B (2003) Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition? J Cancer Res Clin Oncol 129:397-409
20. Kerr BM, Kienzle N, Burrows JM, Cross S, Silins SL, Buck M, et al (1996) Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus. J Virol 70:8858-8864
21. McGuckin MA, Ramm LE, Joy GJ, Devine PL, Ward BG (1993) Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy women. Clin Chim Acta 214:139-151
22. Musselli C, Ragupathi G, Gilewski T, Panageas K, Spinat Y, Livingston PO (2002) Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC-1. Int J Cancer 97:660-667
23. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U (2003a) Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. Int J Cancer 105:221-225
24. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U (2003b) Natural T cell immunity against cancer. Clin Cancer Res 9:4296-4303
25. Noto H, Takahashi T, Makiguchi Y, Hayashi T, Hinoda Y, Imai K (1997) Cytotoxic T-lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol 9:791-798
26. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, et al (2004) Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 27(3):240-253
27. Pecher G, Haring A, Kaiser L, Thiel E (2002) Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51:669-673
28. Pittet MJ, Zippelius A, Valmori D, Speiser DE, Cerottini JC, Romero P (2002) Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol 23:325-328
29. Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanovic S, et al (2003) Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res 9:4376-4386
30. Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA (1998) Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 46:245-252
31. Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, et al (2000) Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 30:2216-2225
32. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, et al (1997) CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100:2757-2765
33. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, van Zanten-Przybysz I, Hummel P, et al (1999) Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol Immunother 48:47-55
34. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB (1997) Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 185:1605-1617
35. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, et al (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70:7569-7579
36. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J (1988) Monoclonal antibodies to epithelial sialomucins recognize epitopes at different cellular sites in adenolymphomas of the parotid gland. Int J Cancer 3:38-44